We haven't given this a lot of attention but it deserves a little. Looks like Viacell is a much larger business (200M market cap vs. our little baby and he moved onto bigger role with more responsibility but this can't be viewed as good for ACUS (except for maye the reduction in salary expense will help with the burn rate). I wonder what he left on the table? Regardless, this company's viability will be up to the FDA.... Call option, indeed.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra